Compound: Pristinamycin IA
SMILES: O=C1O[C@@H]([C@H](NC(=O)c2ncccc2O)C(=O)N[C@@H](C(=O)N3[C@@H](CCC3)C(N([C@H](C(N4[C@H](C(N[C@H]1c5ccccc5)=O)CC(=O)CC4)=O)Cc6ccc(N(C)C)cc6)C)=O)CC)C
InChIKey: YGXCETJZBDTKRY-DZCVGBHJSA-N
Synonyms: Pristinamycin IA, Streptogramin B, Ostreogrycin B, V50XJ0NC3I, Vernamycin B alpha, CHEBI:8417, PA-114B, NSC-92554, 4-(4-(Dimethylamino)-N-methyl-L-phenylalanine)virginiamycin S1, Vernamycin Balpha, N-[(3S,6S,12R,15S,16R,19S,22S)-3-[[4-(dimethylamino)phenyl]methyl]-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide, 4-[4-(Dimethylamino)-N-methyl-L-phenylalanine]virginiamycin S1, NSC92554, Osteogrycin B, Pristinamycin P1, N-((3S,6S,12R,15S,16R,19S,22S)-3-((4-(dimethylamino)phenyl)methyl)-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo(20.4.0.06,10)hexacosan-15-yl)-3-hydroxypyridine-2-carboxamide, RefChem:389288, N-(3-((4-(dimethylamino)phenyl)methyl)-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo(20.4.0.06,10)hexacosan-15-yl)-3-hydroxypyridine-2-carboxamide, Mikamycin B, Mikamycin IA, Antibiotic PA 114B, NSC 92554, 3131-03-1, Virginiamycin B, Vernamycin BA, Vernamycin B.alpha., Pristinamycin P 1, PA 114B, Antibiotic 899, PRISTINAMYCIN 1A, Antibiotic PA 114B1, MIKAMYCIN B [MI], Antibiotic PA 114 B1, UNII-V50XJ0NC3I, STREPTOGRAMIN B [MI], PRISTINAMYCIN IA [MI], VERNAMYCIN B, .ALPHA., CHEMBL1256399, SCHEMBL13176900, SCHEMBL29386427, GTPL12934, HY-A0279A, VERNAMYCIN B.ALPHA. [MI], DTXSID701028335, CS-5850, BRN 0078387, FP172927, N-((6R,9S,10R,13S,15aS,22S,24aS)-22-(4-(dimethylamino)benzyl)-6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12H-pyrido[2,1-f]pyrrolo[2,1-l][1]oxa[4,7,10,13,16]pentaazacyclononadecin-9-yl)-3-hydroxypicolinamide, F85430, 4-27-00-09718 (Beilstein Handbook Reference), Q14035740, Virginiamycin S1, 4-(4(dimethylamino)-N-methyl-L-phenylalanine)-, Vernamycin Balpha; Virginiamycin S1, 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-, N-((3-HYDROXY-2-PYRIDINYL)CARBONYL)-L-THREONYL-(2R)-2-AMINOBUTANOYL-L-PROLYL-4-(DIMETHYLAMINO)-N-METHYL-L-PHENYLALANYL-(2S)-4-OXO-2-PIPERIDINECARBONYL-(2S)-2-PHENYLGLYCINE (6->13)-LACTONE, N-[(6R,9S,10R,13S,15aS,22S,24aS)-22-{[4-(dimethylamino)phenyl]methyl}-6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12H-pyrido[2,1-f]pyrrolo[2,1-l][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl]-3-hydroxypyridine-2-carboxamide
Theoretical properties:
molecular_formula: C45H54N8O10
molecular_weight: 867.0 g/mol
exact_mass: 866.39628995 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 12
rotatable_bond_count: 7
heavy_atom_count: 63
topological_polar_surface_area: 228 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
{"pubchem": "Pristinamycin IA is a cyclodepsipeptide that is (together with pristinamycin IIA) a component of pristinamycin, an oral streptogramin antibiotic produced by Streptomyces pristinaespiralis. Pristinamycin exhibits bactericidal activity against Gram positive organisms including methicillin-resistant Staphylococcus aureus. It has a role as an antimicrobial agent, an antibacterial drug and a bacterial metabolite.", "chebi": "A cyclodepsipeptide that is (together with pristinamycin IIA) a component of pristinamycin, an oral streptogramin antibiotic produced by <em>Streptomyces pristinaespiralis</em>. Pristinamycin exhibits bactericidal activity against Gram positive organisms including methicillin-resistant <em>Staphylococcus aureus</em>.", "chembl": "PRISTINAMYCIN 1A is a unknown listed in the ChEMBL database but has not progressed to an approved clinical phase.", "wikipedia": "Pristinamycin (INN), also spelled pristinamycine, is an antibiotic used primarily in the treatment of staphylococcal infections, and to a lesser extent streptococcal infections. It is a streptogramin group antibiotic, similar to virginiamycin, derived from the bacterium Streptomyces pristinaespiralis. It is marketed in Europe by Sanofi-Aventis under the trade name Pyostacine.\nPristinamycin is a mixture of two components that have a synergistic antibacterial action. Pristinamycin IIA is a macrolide, and results in pristinamycin's having a similar spectrum of action to erythromycin. Pristinamycin IA (streptogramin B) is a depsipeptide. PI and PII are coproduced by S. pristinaespiralis in a ratio of 30:70. Each compound binds to the bacterial 50 S ribosomal subunit and inhibits the elongation process of the protein synthesis, thereby exhibiting only a moderate bacteriostatic activity. However, the combination of both substances acts synergistically and  leads to a potent bactericidal activity that can reach up to 100 times that of the separate components.\nThe pristinamycin biosynthetic gene cluster is the largest antibiotic supercluster known so far, with a size of ~210 kb, wherein the PI and PII biosynthetic genes are not clustered individually but are scattered across the complete sequence region. Furthermore, this biosynthetic gene region is interrupted by a cryptic type II PKS gene cluster.\n\n"}